Born in ELI Beamlines
We started as an electron acceleration research project at ELI Beamlines labs in Europe.
Fighting Cancer with Light-Speed Physics
We are building the world’s first patented laser-plasma accelerator for radiotherapy, unlocking treatment for tumors resistant to conventional care in a compact, cost-effective system born at the world’s top laser science lab.
“Cancer patients are dying not from cancer, but from physics limitations”
Spun out by leading experts
We are an international team of physicists, data scientists, radiation oncologists & med tech entrepreneurs.
On a mission to rewrite what’s possible
Partnering with top bio labs and healthcare institutions around the world to develop new cancer treatment technology.
The Problem
Radiation is a cornerstone of cancer treatment
• 50% of cancer patients require radiotherapy
• It contributes to 40% of all cancer cures
• Yet millions don’t receive it — especially in underserved regions
Outdated tech and infrastructure gaps limit access
• Bulky, expensive linear accelerators require specialized buildings and staff
• In many countries, up to 50% of eligible patients go untreated
Even with access, many tumors resist treatment
• 15–20% of cancers are intrinsically radioresistant, including pancreas, liver, and kidney
• Up to 40% of radiotherapy patients relapse due to acquired resistance
Qure Labs Team
Meet our people
Gabriele Maria Grittani, Co-Founder & CEO
Gabriele is the Leader of Electron Acceleration Group at ELI Beamlines and Deputy Head of Radiation Physics Department. He holds a PhD in Plasma Physics and is the author of 40+ peer-reviewed papers, spearheading the development of the LPA tech behind Qure.
Alex Kovalenko, Co-Founder & CDO
Alex is Assistant Professor, Applied Mathematics at CTU Prague, holds PhD in Theoretical Physics, MSc in Aerospace Engineering and Leads Qure-’s FLASH modeling and VHEE dosimetry simulations.
Carlo Maria Lazzarini, Co-Founder & CTO
Carlo Maria (Physics, Pisa; PhD in Quantum Technology) is a world-leading expert in laser-plasma electron acceleration, with 10+ years at ELI. He built the first compact kHz laser accelerator to record energy and demonstrated its use in pre-clinical radiobiology. At Qure, he leads technology design, from lab to market-ready prototype.
Tomas Studenik, Co-Founder & CMO
Tomas is the founder of Caelestinus Health Tech Incubator, organizer of largest hospital hackathons in Europe as well as angel investor. At Qure, he is driving sales, marketing and partnerships activities.
Why Choose Qure Health Technologies?
Qure is the world’s first laser-plasma accelerator for cancer care
Miniaturization through extreme field gradients
Traditional RF accelerators: ~20 MV/m
LPAs achieve up to 100 GV/m - over 5,000× higher
Qure shrinks the beamline from 20 m to under 2 m - no gantry, no bunker
Radiobiological superiority with VHEE + FLASH
VHEE (Very High Energy Electrons) penetrate 20–30 cm with minimal lateral scatter
Enables precise dose sculpting for deep-seated, irregular tumors
FLASH dose rates (>10⁶ Gy/s) shown to spare healthy tissue while preserving tumor control
Built-in shielding + sustainability
Electron beams produce ~1,000× fewer neutrons than high-energy X-rays
Drastically reduces bunker size, cost, and decommissioning complexity
Lower wall-plug power + HVAC demand = better energy profile than RF LINACs
Our papers
This is a pick of our scientific papers published by Qure Labs co-founders.
Prototype-Clinical Study Fit
Recent paper (August 2026, Nature Scientific Reports) demonstrating the lab prototype we built can be used for pre-clinical studies on cancer:
New Medical Beam Applications
Highlight/interview from American Institute of Physics on previous paper showing the possibility of new medical applications with our beams:
World Record Beams Paper
Original paper on world record beams: